IGES Experten vor Ort
05.11.24
Fabian Berkemeier | IGES Gruppe
Moderation
Panel: "Pay The Price": Reimbursement - is there now a single HTA procedure in the European Union?
In the European Union (EU), medicines are authorized centrally, but reimbursement is carried out at the national level: the EU member states conduct national assessment procedures for this purpose, known as health technology assessments (HTAs). Harmonization of these procedures is one of the most important innovations in the regulatory framework for medicines in Europe. From January 2025, a common clinical assessment will come into force in the EU. This will be introduced gradually, starting with cancer medicines (including orphan oncology drugs) and ATMPs. A whole series of important EU regulations came into force in 2024. Currently, national regulations are being adapted to the new European procedure in the EU member states. And now, in the fall of 2024, many details regarding the implementation and execution of the new procedure are clarified. This panel will discuss how small and large biopharmaceutical companies need to adapt to the new procedure to reach Europe’s patients quickly and successfully with their innovative therapies.
Panelists:
- Niklas Hedberg |The Swedish Dental and Pharmaceutical Benefits Agency
- Sophia Heigis | Oncopeptides
- Gry Stine Kopperud | Novartis
- Alexander Natz | EUCOPE
Veranstaltung: BIO-EUROPE 2024
Kongress
Ort: Stockholmsmässan Mässvägen 1, 125 30 Älvsjö Stockholm
Raum: Exhibit Hall Stage
Veranstaltungssprache: Englisch
Zeit: 14.00 - 14.45 Uhr
